Romiplostim plus ESAs for dialysis anemia
Treatments studied
This trial tests whether adding romiplostim (a medication that helps increase blood cells) to standard ESA therapy can improve anemia in people on dialysis who have not responded well to ESAs alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You are on long-term hemodialysis for kidney failure.
- You have not responded well to previous ESA treatment (e.g., epoetin or darbepoetin) or needed high doses without seeing improvement.
- You are currently receiving darbepoetin or Mircera for anemia and taking iron supplements.
- You have anemia symptoms with hemoglobin below 9.5 g/dL (without transfusion) or need blood transfusions regularly.
- You do not have anemia from other causes (like iron deficiency, bleeding, or blood disorders) and have no recent cancer, heart attack, or stroke.
- You can attend frequent blood tests and sign consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called Efepoetin Alfa to treat anemia in people with chronic kidney disease who are on dialysis. The goal is to see if it can safely raise red blood cell levels and reduce the need for other anemia treatments.
This trial tests a drug called romiplostim for people with aplastic anemia that did not get better with standard treatments. It aims to boost blood cell counts and may help reduce the need for transfusions.
This trial tests an oral medication (AND017) for anemia caused by chronic kidney disease. It aims to improve red blood cell levels without needing dialysis or current anemia treatments.
This trial tests a new oral medicine (AND017) for people on dialysis who have anemia (low red blood cells). It may help reduce the need for injections of standard anemia medicines.
This trial tests whether adding romiplostim, a drug that helps the body make platelets, to the usual treatment for severe aplastic anemia can improve blood cell counts. It is for people who have not yet started treatment for this condition.
This study looks at why some people on dialysis don't respond well to anemia medicines (called ESAs). It aims to help doctors understand and better treat anemia in dialysis patients.
Hear when a new Anemia Associated With Chronic Kidney Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.